CNS market resurgence: a decade-long slump ends with $80bn milestone
The CNS market’s decade-long stagnation was driven by the high cost, complexity, and risk of drug development.
Drug Development
BioVersys secures patent claims in China for BV100
Apollomics and LaunXP agree on NSCLC treatment in Asia
ACC 2025: Imbria’s ninerafaxstat data shows potential for cardiometabolic HFpEF
Saving shelved ultra-rare therapies through unorthodox funding
Weill Cancer Hub East launches to transform treatment
Soleno wins FDA approval for Prader-Willi hyperphagia treatment
Ionis and Sobi agree on olezarsen commercialisation
